So presumably, it is up tp Chiesi Global Rare Diseases ( unit of Chiesi Group) to move BTI xB3 BBB platform forward to a Phase 1 clinical trial at their expense. And likewise for any other potential partner or partners licensed to do so.

Is this how BTI be moving forward, by way of multi partnering, with deals similar to Chiesi's?

Koo